Stocks · News reference
Genmab and AbbVie will present 22 abstracts, including Phase 3 data for epcoritamab, at the 68th American Society of Hematology Annual Meeting.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Ichnos Glenmark Innovation will present updated Phase 1 clinical data for the trispecific T-cell engager ISB 2001, developed in partnership with AbbVie, at the ASH Annual Meeting.
Genmab announced that 22 abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody, will be presented at the 2026 ASH Annual Meeting in December. Highlights include first presentation of Phase 3 EPCORE DLBCL-4 study results showing epcoritamab plus lenalidomide in relapsed/refractory DLBCL, along with updated data from multiple trials across B-cell malignancies demonstrating the drug's versatility as monotherapy and in combinations.
AbbVie has secured exclusive global rights to develop and commercialize Nxera Pharma's EP4 receptor agonist program, including the investigational drug NXE0033744, for the treatment of inflammatory bowel disease.
Nxera Pharma has revised its 2026 financial forecast upward following an exclusive global license agreement with AbbVie for its EP4 agonist program NXE0033744. Nxera will receive a US$100 million upfront payment, expected to be recognized in Q4 2026, along with potential milestone payments up to US$1.37 billion and tiered royalties. The revised forecast now projects revenue of JPY48.8 billion, core operating profit of JPY22.8 billion, and operating profit of JPY15.7 billion for 2026.
Allergan Aesthetics, an AbbVie company, will present nine abstracts at the upcoming American Society for Dermatologic Surgery Annual Meeting.
BNP Paribas has updated its price target for AbbVie Inc., raising it from $247 to $269.